{
  "extraction_metadata": {
    "timestamp": "2025-10-02T18:21:16.066135",
    "source_type": "clinical_guideline",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "total_countries": 11,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "AT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "AT",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to deterioration, time to progression of the tumor, intraoperative complications, mortality, morbidity",
      "ChunksUsed": 8,
      "ContextTokens": 2059
    },
    "BE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "BE",
      "Outcomes": "partial response, survival, objective response, liver failure, pain, fever, serious complications, recurrence, tumour growth, needle tract seeding, portal vein thrombosis, adverse events (general)",
      "ChunksUsed": 8,
      "ContextTokens": 1885
    },
    "DE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DE",
      "Outcomes": "overall survival, progression-free survival, partial response, complete remission, time to deterioration, time to progression of the tumor, intraoperative complications, mortality, morbidity",
      "ChunksUsed": 8,
      "ContextTokens": 2059
    },
    "DK": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "DK",
      "Outcomes": "long-term survival, perioperative mortality, morbidity, leukaemia, postoperative softening, gallbladder abscess, recurrence, prognosis (assessed by diameter of largest tumour and number of tumours in the liver), extrahepatic tumour presence, microinvasion, tumour invasion in larger portal branches, distant metastases, thrombosis of the venae portae, thrombosis of the vena cavae main stem, performance status, severity of underlying liver disease",
      "ChunksUsed": 8,
      "ContextTokens": 1421
    },
    "ES": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "ES",
      "Outcomes": "survival, median survival (by HCC stage), therapeutic efficacy, recurrence detection, long-term treatment-related complications",
      "ChunksUsed": 8,
      "ContextTokens": 1633
    },
    "EU": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "EU",
      "Outcomes": "HCC-related mortality",
      "ChunksUsed": 8,
      "ContextTokens": 2242
    },
    "FR": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "FR",
      "Outcomes": "time-to-progression, toxicity, overall survival, response rates, adverse events, diarrhoea, fatigue, nausea, neutropenia, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 8,
      "ContextTokens": 2444
    },
    "IT": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "IT",
      "Outcomes": "improved survival, response rates, adverse events, Child-Pugh score, MELD score, rebleeding, liver-related morbidity, liver-related mortality, portal vein thrombosis, cost-effectiveness, false positives, hypersensitivity to monitoring, severe HCC, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 8,
      "ContextTokens": 1960
    },
    "NL": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "NL",
      "Outcomes": "overall survival, progression-free survivorship, response rate, adverse events, adverse events (Grade â‰¥ 3), quality of life, overall quality of life (measured with a validated and reliable instrument), tumour response rate, local tumour control, success rate (downstaging/bridging), complications",
      "ChunksUsed": 8,
      "ContextTokens": 2017
    },
    "PO": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "PO",
      "Outcomes": "progression assessment (BCLC assessment system), response rates (RECIST criteria for locoregional therapies), response rates (mRECIST for systemic therapy), response rates (RECIS systems for systemic therapy), response assessment (multiphase computed tomography with contrast), response assessment (magnetic resonance imaging with contrast), perioperative mortality, mortality rate, adverse events (general)",
      "ChunksUsed": 8,
      "ContextTokens": 1798
    },
    "SE": {
      "Indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
      "Country": "SE",
      "Outcomes": "EORTC QLQ-30, FACT-G, EORTC QLQ-HCC18, FACT-Hep, survival, prognosis, varicose vein bleeding, clinically detectable ascites, hepatic encephalopathy (grade > 1 on the New Haven criteria)",
      "ChunksUsed": 8,
      "ContextTokens": 1459
    }
  }
}